Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01012440 · ClinicalTrials.gov registry record · NA
Role of Positron Emission Mammography (PEM) Flex Solo II Positron Emission Tomography (PET) Scanner in Evaluating Neoadjuvant Chemotherapy Response in Patients With Breast Cancer
A NA study, sponsored by University of Chicago.
- Terminated
- Registry status
- NA
- Development phase
- 5
- Enrollment target
NCT01012440 is a NA study that was terminated before completion, run by University of Chicago. The registered enrollment target is 5 participants.
The verdict
NCT01012440, a NA study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is: 1. To evaluate the hypothesis: Can PEM Flex Solo II PET scanner ascertain response to neoadjuvant chemotherapy in patients with breast cancer? 2. To compare the results from the PEM Flex Solo II PET scanner to the standard of care bilateral breast MRI.
Interventions
- DEVICE MRI scan
- DEVICE PEM Flex Solo II PET Scanner
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2009-11 |
| Est. Completion | 2012-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01012440
The ClinicalTrials.gov registry entry for NCT01012440 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MRI scan is the first listed.
NCT01012440 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01012440 about?
NCT01012440 is a clinical study titled "Role of Positron Emission Mammography (PEM) Flex Solo II Positron Emission Tomography (PET) Scanner in Evaluating Neoadjuvant Chemotherapy Response in Patients With Breast Cancer". The purpose of this study is: 1. To evaluate the hypothesis: Can PEM Flex Solo II PET scanner ascertain response to neoadjuvant chemotherapy in patients with breast cancer? 2. To compare the results from the PEM Flex Solo II PET scanner to the standard of care bilateral breast MRI.
What is the current status of trial NCT01012440?
This trial is currently terminated. It is a NA study. The enrollment target is 5 participants. The study started on 2009-11. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01012440?
The interventions under investigation include: MRI scan (DEVICE), PEM Flex Solo II PET Scanner (DEVICE).
Who is sponsoring clinical trial NCT01012440?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.